Patents by Inventor James David Winkler

James David Winkler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Beta lactams as antiproliferative agents
    Patent number: 6451785
    Abstract: A method of inhibiting or reducing cell proliferation in a human or mammal is disclosed. This method involves administering to a human or mammal an effective amount of CoA-independent transacylase inhibiting amount of a compound of the formula disclosed in the specification.
    Type: Grant
    Filed: January 28, 2000
    Date of Patent: September 17, 2002
    Assignees: SmithKline Beecham Corporation, Wake Forest University
    Inventors: James David Winkler, Floyd Harold Chilton, III
  • BETA LACTAMS AS ANTIPROLIFERATIVE AGENTS
    Publication number: 20020082250
    Abstract: This invention relates to a method of treating or reducing cell proliferation in a mammal in need thereof which comprises administering to said mammal an effective CoA-independent transacylase (CoA-IT) inhibiting amount of a compound of formula (I), wherein the variables of Y, X, m, R 3, R 4, R 10, R 20, R 5, R 6 and R 7 are defined in the specification. FIG. 3 demonstrates the ability of SB216754, ((3S,4R)-4-(isobutenyloxy)-3-triphenylmethylamino)azetidin-2-one) to decrease the viability of HL-60 cells.
    Type: Application
    Filed: January 28, 2000
    Publication date: June 27, 2002
    Inventors: JAMES DAVID WINKLER, FLOYD HAROLD CHILTON III
  • Beta-lactam inhibitors of CoA-IT
    Patent number: 6221860
    Abstract: This invention relates to methods for treating diseases or disorders mediated by lipid inflammatory mediators, arachidonic acid, its metabolites and/or platelet activating factor (PAF), which method comprises administration to a mammal in need thereof of an effective Coenzyme A independent transacylase (CoA-IT) inhibiting amount of a triphenylmethylazetidinone. This invention also relates to a method of treating or reducing inflammation in a mammal in need thereof, which comprises administering to said mammal an effective amount of a triphenylmethylazetidinone.
    Type: Grant
    Filed: November 8, 1999
    Date of Patent: April 24, 2001
    Assignee: SmithKline Beecham Corporation
    Inventors: William E. Bondinell, James David Winkler
  • Anti-inflammatory compounds
    Patent number: 5912270
    Abstract: This invention relates to the novel pharmaceutical compositions of Formulas (I) and (II) each of which comprises a compound of Formula (I) or (II) and a pharmaceutically acceptable diluent or carrier. This invention also relates to a method of treating or reducing inflammation in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound or composition of Formula (I) or (II).
    Type: Grant
    Filed: November 22, 1996
    Date of Patent: June 15, 1999
    Assignees: SmithKline Beecham Corporation, The Johns Hopkins University
    Inventors: James Scott Dixon, Ralph Floyd Hall, Lisa Ann Marshall, Floyd H. Chilton, III, Ruth Judik Mayer, James David Winkler
  • Inhibition of inflammatory lipid mediators
    Patent number: 5663053
    Abstract: Coenzyme A-independent transacylase is required for the release of free arachidonic acid, and the production of arachidonic acid metabolites and platelet activation factor. Blocking of this enzyme inhibits the production of these inflammatory mediators and will be of therapeutic utility in a broad range of allergic and inflammatory diseases and disorders. Compounds are described herein which inhibit the action of CoA-IT and are therefore useful in the treatment of disease states caused thereby.
    Type: Grant
    Filed: November 30, 1994
    Date of Patent: September 2, 1997
    Assignees: SmithKline Beecham Corporation, The Johns Hopkins University
    Inventors: James David Winkler, Deirdre Mary Bernadette Hickey, Floyd Harold Chilton, III
  • CoA-IT and PAF inhibitors
    Patent number: 5648373
    Abstract: Coenzyme A-independent transacylase is required for the release of free arachidonic acid, and the production of arachidonic acid metabolites and platelet activation factor. Blocking of this enzyme inhibits the production of these inflammatory mediators and will be of therapeutic utility in a broad range of allergic and inflammatory diseases and disorders. Compounds are described herein which inhibit the action of CoA-IT and are therefore useful in the treatment of disease states caused thereby.
    Type: Grant
    Filed: August 6, 1993
    Date of Patent: July 15, 1997
    Assignees: SmithKline Beecham Corporation, The Johns Hopkins University
    Inventors: James David Winkler, Floyd Harold Chilton, III, Deirdre Mary Bernadette Hickey